Activation of the mitogen-activated protein kinase–extracellular signal-regulated kinase pathway in childhood B-cell acute lymphoblastic leukemia

Pallavi M. Pillai, Nicole Mallory, Joanna Pierro, Jason Saliba, Daniel Newman, Jiyuan Hu, Teena Bhatla, Elizabeth Raetz, William L. Carroll, Nikki A. Evensen

Research output: Contribution to journalArticlepeer-review

Abstract

RAS mutations are frequently observed in childhood B-cell acute lymphoblastic leukemia (B-ALL) and previous studies have yielded conflicting results as to whether they are associated with a poor outcome. We and others have demonstrated that the mitogen-activated protein kinase–extracellular signal-regulated kinase (MAPK) pathway can be activated through epigenetic mechanisms in the absence of RAS pathway mutations. Herein, we examined whether MAPK activation, as determined by measuring phosphorylated extracellular signal-regulated kinase (pERK) levels in 80 diagnostic patient samples using phosphoflow cytometry, could be used as a prognostic biomarker for pediatric B-ALL. The mean fluorescence intensity of pERK (MFI) was measured at baseline and after exogenous stimulation with or without pretreatment with the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib. Activation levels (MFI stimulated/MFI baseline) ranged from 0.76 to 4.40 (median = 1.26), and inhibition indexes (MFI stimulated/MFI trametinib stimulated) ranged from 0.439 to 5.640 (median = 1.30), with no significant difference between patients with wildtype versus mutant RAS for either. Logistic regression demonstrated that neither MAPK activation levels nor RAS mutation status at diagnosis alone or in combination was prognostic of outcome. However, 35% of RAS wildtype samples showed MAPK inhibition indexes greater than the median, thus raising the possibility that therapeutic strategies to inhibit MAPK activation may not be restricted to patients whose blasts display Ras pathway defects.

Original languageEnglish
Article numbere29771
JournalPediatric Blood and Cancer
Volume69
Issue number10
DOIs
StatePublished - Oct 2022

Keywords

  • MAPK pathway
  • RAS
  • pediatric acute lymphoblastic leukemia
  • phosphoflow cytometry

Fingerprint

Dive into the research topics of 'Activation of the mitogen-activated protein kinase–extracellular signal-regulated kinase pathway in childhood B-cell acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this